News | Cardiovascular Surgery | May 03, 2019

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease

Study reinforces value of heart team approach when making treatment decisions

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease

May 3, 2019 — Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one blocked heart artery, according to research published online in The Annals of Thoracic Surgery.1

“Our data demonstrate a significant mortality benefit with CABG over percutaneous coronary intervention (PCI), and this benefit is consistent across virtually all major patient groups, suggesting that CABG should be considered in broader patient populations, not just in cases of patients with diabetes and left ventricular dysfunction, which is what is commonly practiced,” said lead author Suresh R. Mulukutla, M.D., from the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.

Mulukutla and colleagues examined data from two major clinical outcomes registries for heart patients — The Society of Thoracic Surgeons (STS) National Database and the American College of Cardiology Foundation National Cardiovascular Data Registry (NCDR). The researchers identified patients with multivessel coronary artery disease who underwent CABG or PCI between 2010 and 2018 at UPMC. Those who met the eligibility criteria were separated into two groups — CABG and PCI — each including 844 patients. The analyses focused on outcomes for mortality, readmission and revascularization.

The researchers found that the estimated one-year mortality for patients in the CABG group was 7.2 percent, as compared to 11.5 percent the PCI group. The CABG group also experienced lower risk of hospital readmission (28.1 percent vs. 38.4 percent) and revascularization (1 percent vs. 6.7 percent) than the PCI group.

“A major point in the study is the focus on the current era of revascularization with the most currently available stents,” said Mulukutla. “This research is really a modern, ‘real-world’ experience. While randomized clinical trials are clearly important, real-world analyses also can be very instructive because they provide insights on how we are making clinical decisions. For instance, the last several years have seen a shift toward more PCI over CABG. While there may be valid reasons for this, our data — which show CABG outperforming PCI in almost every patient group — should push us to further discuss all of the options.”

PCI, often referred to as angioplasty, is a nonsurgical procedure that uses a thin, flexible catheter placed into an artery in the groin or arm. A balloon on the end of the catheter is positioned in the narrowed coronary artery and inflated to open up the blockage. A stent is a metal mesh tube that is left behind to help keep the artery from collapsing. Drugs attached to the stent help prevent the body from reacting to the stent and shutting down the artery again.

CABG, the most commonly performed heart operation in the United States, is designed to bypass the blockages in the coronary arteries in order to create a new path for blood flow to the heart. The surgeon removes a healthy blood vessel, usually from the leg, arm, chest or abdomen, and connects it to the other arteries (usually the aorta) in the heart. This enables blood flow to go around the diseased or blocked portion of the coronary artery.

The decision between open heart surgery and PCI for treatment of patients with multiple narrowed arteries is not always straightforward, according to Mulukutla. Thus, these more complex treatment decisions should be made with the guidance of a heart care team.

“Both cardiac surgery and stenting have roles among patients with coronary artery disease,” said Mulukutla. “Because of this, it is important to deliberate carefully with the help of a heart team. The team can ensure that a multidisciplinary approach is used when offering recommendations to patients and assisting them in making informed decisions.”

A heart care team generally includes cardiothoracic surgeons and cardiologists. Other healthcare providers such as primary care physicians, physician assistants, nurse practitioners, imaging specialists and anesthesiologists also may be part of the team. This approach leverages the expertise of these advanced practice providers in an effort to improve the efficiency and advance the quality of care for patients.

With revascularization, heart team input is often limited because PCI can be completed at the time of a patient’s diagnostic procedure. When this happens, the physicians do not have the opportunity to discuss the spectrum of possible treatment options. As a result, the practical and consistent use of the heart team for decision-making in the treatment of patients with complex coronary artery diseases is lacking, Mulukutla explained.

“We are working to better facilitate a heart team approach and overcome some of the limitations given the current infrastructure of how these decisions are made,” said Mulukutla. “We also are continuing to identify specific patient populations that may benefit from either CABG or PCI so that we can best advocate for our patients.”

For more information: www.annalsthoracicsurgery.org

 

Reference

1. Mulukutla S.R., Gleason T.G., Sharbaugh M., et al. Coronary Bypass Versus Percutaneous Revascularization in Multivessel Coronary Artery Disease. Annals of Thoracic Surgery, published online May 1, 2019. DOI: 10.1016/j.athoracsur.2019.02.064.


Related Content

News | Cardiovascular Clinical Studies

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
Subscribe Now